Format
Sort by

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 69

1.

Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases.

Murata K, Nose M, Ndhlovu LC, Sato T, Sugamura K, Ishii N.

J Immunol. 2002 Oct 15;169(8):4628-36.

2.

Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation.

Arestides RS, He H, Westlake RM, Chen AI, Sharpe AH, Perkins DL, Finn PW.

Eur J Immunol. 2002 Oct;32(10):2874-80.

3.

Signaling of gp34 (OX40 ligand) induces vascular endothelial cells to produce a CC chemokine RANTES/CCL5.

Kotani A, Hori T, Matsumura Y, Uchiyama T.

Immunol Lett. 2002 Oct 21;84(1):1-7.

PMID:
12161277
4.

Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134).

Petty JK, He K, Corless CL, Vetto JT, Weinberg AD.

Am J Surg. 2002 May;183(5):512-8.

PMID:
12034383
5.
6.

Expression of OX40 in muscles of polymyositis and granulomatous myopathy.

Tateyama M, Fujihara K, Ishii N, Sugamura K, Onodera Y, Itoyama Y.

J Neurol Sci. 2002 Feb 15;194(1):29-34.

PMID:
11809163
8.

OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells.

Rogers PR, Song J, Gramaglia I, Killeen N, Croft M.

Immunity. 2001 Sep;15(3):445-55.

9.

Normal IgG protects against acute graft-versus-host disease by targeting CD4(+)CD134(+) donor alloreactive T cells.

Caccavelli L, Field AC, Betin V, Dreillard L, Belair MF, Bloch MF, Bruneval P, Kazatchkine M, Bellon B.

Eur J Immunol. 2001 Sep;31(9):2781-90.

10.

Signaling through OX40 (CD134) breaks peripheral T-cell tolerance.

Bansal-Pakala P, Jember AG, Croft M.

Nat Med. 2001 Aug;7(8):907-12.

PMID:
11479622
11.

CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice.

Malmström V, Shipton D, Singh B, Al-Shamkhani A, Puklavec MJ, Barclay AN, Powrie F.

J Immunol. 2001 Jun 1;166(11):6972-81.

12.

Expression of gp34 (OX40 ligand) and OX40 on human T cell clones.

Takasawa N, Ishii N, Higashimura N, Murata K, Tanaka Y, Nakamura M, Sasaki T, Sugamura K.

Jpn J Cancer Res. 2001 Apr;92(4):377-82.

PMID:
11346458
13.
14.
15.

Expression of OX40 and OX40 ligand (gp34) in the normal and myasthenic thymus.

Onodera J, Nagata T, Fujihara K, Ohuchi M, Ishii N, Sugamura K, Itoyama Y.

Acta Neurol Scand. 2000 Oct;102(4):236-43.

PMID:
11071109
16.

Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis.

Yoshioka T, Nakajima A, Akiba H, Ishiwata T, Asano G, Yoshino S, Yagita H, Okumura K.

Eur J Immunol. 2000 Oct;30(10):2815-23.

17.

Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.

Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S.

Cancer Res. 2000 Oct 1;60(19):5514-21.

18.

The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion.

Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M.

J Immunol. 2000 Sep 15;165(6):3043-50.

19.
20.

Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis.

Aten J, Roos A, Claessen N, Schilder-Tol EJ, Ten Berge IJ, Weening JJ.

J Am Soc Nephrol. 2000 Aug;11(8):1426-38.

Items per page

Supplemental Content

Write to the Help Desk